Statistics

Total Visits

Views
Weekly cabazitaxel in "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. CABASEM-SOGUG phase II trial50

Select a period of time:

Number of views in the range

Views
Weekly cabazitaxel in "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. CABASEM-SOGUG phase II trial31

Views

Views
June 20251
July 202521
August 20252
September 20253
October 20252
November 20252
December 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil13
United States7
Chile2
Argentina1
Colombia1
Ecuador1
United Kingdom1
Honduras1
Turkey1
Trinidad and Tobago1
 

Top cities views

Views
Santiago2
Porto Alegre2
Cape Town1
Chaguanas1
Charlotte1
Columbia1
Curitiba1
Curvelo1
Dallas1
El Progreso1